Bausch Health Companies Inc.

BHC

CA0717341071

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Employees

20,270

Sector

Pharmaceuticals

Calendar

2024-10-30 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

8.030USD

Average target price

7.786USD

Spread / Average Target

-3.04%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 16:00:02 2024-09-18 EDT			5-day change	1st Jan Change
8.020 ^USD	+11.70%		+28.32%	0.00%

09-16	Sector Update: Health Care	MT
09-16	Bausch + Lomb Explores Sale Amid Debt. Spinoff Hurdles	MT

Sector Update: Health Care	09-16	MT
Bausch + Lomb Explores Sale Amid Debt. Spinoff Hurdles	09-16	MT
Bausch + Lomb Reportedly Explores Sale Amid Debt and Spin-Off Challenges	09-16	MT
Trump Allies Discussing Plans to Privatize Fannie Mae, Freddie Mac	09-16	MT
Bausch + Lomb Sale Would Make Sense Given Valuation	09-13	CI
Trump Allies Discussing Plans to Privatize Fannie Mae, Freddie Mac	09-13	MT
Bausch Health Companies Says Cabtreo Gets Health Canada Approval	09-11	MT
Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel	09-11	CI
Milestone Pharmaceuticals Appoints Joseph Papa to Its Board of Directors	09-04	CI
Health Care Up on Lilly's Blockbuster Earnings -- Health Care Roundup	08-08	DJ
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	08-08	MT
Sector Update: Health Care	08-08	MT
Bausch Health Eye-Care Unit Spinoff Stalls Amid Shareholders, Creditors Disagreement	08-08	MT
Bausch Health's Eye-Care Unit Spinoff Stalled Amid Shareholders' Dispute With Creditors, WSJ Reports	08-08	MT
RBC Cuts Bausch Health Price Target to US$8.50, Maintains Sector Perform	08-02	MT
TSX hits over three-week low as US jobs data adds to recession worries	08-02	RE
Exchange-Traded Funds, Equity Futures Lower Pre-Bell as Technology Stocks, July Jobless Rate Raise Investor Concerns	08-02	MT
RBC Cuts Price Target on Bausch Health to $8.50 From $10, Keeps Sector Perform Rating	08-02	MT
Top Premarket Decliners	08-02	MT
Piper Sandler Downgrades Bausch Health to Underweight From Neutral, Adjusts Price Target to $3 From $9	08-02	MT
Bausch Health Companies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-01	CI
Bausch Health Shares Rise Following Q2 Results, Higher 2024 Outlook	08-01	MT
Bausch Health Q2 Adjusted Profit Declines, Revenue up 11%; Revenue Guidance Raised	08-01	MT
Transcript : Bausch Health Companies Inc., Q2 2024 Earnings Call, Aug 01, 2024	08-01
Bausch Health Brief: Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	08-01	MT

Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Pharmaceuticals

Latest news about Bausch Health Companies Inc.

Chart Bausch Health Companies Inc.

Company Profile

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise